Breaking news from Project ALS Autophagy Team: Study in mice reveals that the body’s own defense against ALS actually drives disease progression at later stages.
New York, NY and Cambridge, MA (September 7, 2017) – Project ALS and Amylyx Pharmaceuticals today announced a collaboration to undertake pre-clinical studies with Amylyx’s oral
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur
Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur
Project ALS researcher Dr. Tom Maniatis, Columbia University, gives an update on ALS research.
Project ALS funds critical drug testing at Columbia University and Massachusetts General Hospital/Harvard Medical School. The Project ALS Pre-Clinical Core at Columbia is currently testing
The world is closer to understanding the causes of ALS. However, the most important power source in the fight to find medicine these days is…patients
Project ALS funds a four-lab consortium working to understand why the motor neurons controlling the eye movement—ocular motor neurons, or OMNs—remain functional in ALS, while
Project ALS is pleased to share that the FDA has approved the drug edaravone – the first approved ALS treatment in over 20 years. Edaravone,
